BGB-3111-308

• Research type

  Research Study

• Full title

  A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

• IRAS ID

  1006973

• Contact name

  Kajal Patel

• Contact email

  kajal.patel@beigene.com

• Sponsor organisation

  BeiGene Switzerland GmbH

• Research summary

  This is a randomized, open-label study for Relapsed/Refractory Follicular Lymphoma (R/R FL) or Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL), which means that the participants, study doctor and the research team know that the participant is receiving study drug and know which treatment arm the participant is allocated. This study has 4 treatment arms for 2 cohorts and will be enrolled and randomized in a 1:1 ratio; For participants who are R/R FL Arm A-Zanubrutinib plus Obinutuzumab (ZO), Arm B-Lenalidomide plus Rituximab (R2), and for participants who are R/R MZL Arm C-Zanubrutinib plus Rituximab (ZR), Arm D-Lenalidomide plus Rituximab (R2). The study will determine if ZO or ZR can improve outcomes in participants with R/R FL or MZL.

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  23/SC/0141

• Date of REC Opinion

  3 Oct 2023

• REC opinion

  Further Information Favourable Opinion